← Back to Search

Antiplatelet agent

Tricagrelor for Bleeding

Phase 4
Waitlist Available
Led By Mandeep Singh, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, approximately 90 days.
Awards & highlights

Study Summary

This trial is testing whether it is safe to reduce the time patients are on two blood-thinning medications after having a coronary stent placed.

Eligible Conditions
  • Bleeding Complications

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, approximately 90 days.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, approximately 90 days. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ischemic Risk Post-PCI in High Bleed Risk Patients With Genotype-guided Single Antiplatelet Therapy

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Genotype-Guided TherapyExperimental Treatment2 Interventions
Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 loss-of-function (LOF) allele within one week of DAPT initiation. In this group, subjects identified as CYP2C19*2 or*3 LOF allele carrier will be given prasugrel or ticagrelor monotherapy.
Group II: Conventional TherapyActive Control1 Intervention
Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 loss-of-function (LOF) allele within one week of DAPT initiation. In this group, subjects identified as CYp2C19*2 or*3 LOF allele non-carriers will continue with clopidogrel monotherapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Prasugrel
FDA approved
Tricagrelor
2022
Completed Phase 4
~100

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,239 Previous Clinical Trials
3,771,501 Total Patients Enrolled
5 Trials studying Bleeding
14,176 Patients Enrolled for Bleeding
Mandeep Singh, MDPrincipal InvestigatorMayo Clinic
5 Previous Clinical Trials
240 Total Patients Enrolled
~32 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top